We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Members of the Senate Special Committee on Aging took Valeant Pharmaceuticals’ International officials to task over what they called the company’s practice of buying drugs with no generic competition and “jacking up” the prices. Read More
As expected, Pfizer will pay $784.6 million to settle Justice Department allegations that a subsidiary deliberately reported inflated prices to Medicaid for two drugs. Read More
Despite grave doubts, an Indian high court judge is allowing two drugmakers to market and produce contested biosimilars of Roche’s breast cancer therapy Herceptin. Read More
The House Energy and Commerce Committee is scheduled to mark up a bill Wednesday that would encourage the development of abuse-deterrent opioids. Read More
In a change of heart from earlier draft guidance, the UK’s National Institute for Health and Care Excellence has recommended reimbursement for Sanofi’s Jevtana for treating prostate cancer. Read More
GlaxoSmithKline is appealing a $54 million fine from the UK’s Competitions and Market Authority over pay-for-delay allegations, contending the company’s conduct was “objectively justified.” Read More